As global markets navigate a landscape marked by trade negotiations and economic uncertainty, Asia's financial scene remains a focal point for investors seeking opportunities amid evolving conditions. Penny stocks, though an older term, still capture the essence of investing in smaller or emerging companies that can offer significant value. By focusing on those with strong financials and potential growth paths, investors may uncover hidden gems within this segment of the market.
Top 10 Penny Stocks In Asia
| Name | Share Price | Market Cap | Rewards & Risks |
| Advice IT Infinite (SET:ADVICE) | THB4.90 | THB3.04B | ✅ 4 ⚠️ 3 View Analysis > |
| T.A.C. Consumer (SET:TACC) | THB4.58 | THB2.75B | ✅ 4 ⚠️ 3 View Analysis > |
| Tirathai (SET:TRT) | THB3.18 | THB979.47M | ✅ 2 ⚠️ 3 View Analysis > |
| CNMC Goldmine Holdings (Catalist:5TP) | SGD0.41 | SGD166.17M | ✅ 4 ⚠️ 3 View Analysis > |
| Beng Kuang Marine (SGX:BEZ) | SGD0.186 | SGD37.05M | ✅ 4 ⚠️ 3 View Analysis > |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) | SGD2.21 | SGD8.7B | ✅ 5 ⚠️ 0 View Analysis > |
| Bosideng International Holdings (SEHK:3998) | HK$4.12 | HK$47.17B | ✅ 4 ⚠️ 1 View Analysis > |
| Lever Style (SEHK:1346) | HK$1.17 | HK$738.21M | ✅ 4 ⚠️ 2 View Analysis > |
| Goodbaby International Holdings (SEHK:1086) | HK$1.38 | HK$2.3B | ✅ 3 ⚠️ 2 View Analysis > |
| TK Group (Holdings) (SEHK:2283) | HK$2.18 | HK$1.82B | ✅ 3 ⚠️ 1 View Analysis > |
Click here to see the full list of 1,174 stocks from our Asian Penny Stocks screener.
Let's review some notable picks from our screened stocks.
Viva Biotech Holdings (SEHK:1873)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Viva Biotech Holdings is an investment holding company that provides structure-based drug discovery services to biotechnology and pharmaceutical customers globally, with a market cap of HK$3.37 billion.
Operations: The company's revenue is primarily derived from its Drug Discovery Services, which generated CN¥821.31 million, and its Contract Development Manufacture Organisation (CDMO) and Commercialisation Services, contributing CN¥1.18 billion.
Market Cap: HK$3.37B
Viva Biotech Holdings has shown a significant turnaround, reporting a net income of CN¥167.29 million for 2024, compared to a loss the previous year. The company's revenue streams are primarily from Drug Discovery Services and CDMO services, totaling CN¥1.99 billion. Despite high share price volatility and an increased debt-to-equity ratio over five years, its debt is well covered by operating cash flow and interest payments are adequately managed with EBIT coverage of 6.9 times. Recent board changes aim to enhance governance amid improving operational efficiency and investment gains contributing to profitability recovery.
- Click here and access our complete financial health analysis report to understand the dynamics of Viva Biotech Holdings.
- Evaluate Viva Biotech Holdings' prospects by accessing our earnings growth report.
Tian An China Investments (SEHK:28)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Tian An China Investments Company Limited is an investment holding company that focuses on investing in, developing, and managing properties in the People's Republic of China, Hong Kong, and the United Kingdom with a market cap of HK$6.45 billion.
Operations: The company's revenue segments include Healthcare (HK$1.58 billion), Property Investment (HK$583.52 million), and Property Development (HK$520.46 million).
Market Cap: HK$6.45B
Tian An China Investments has experienced a challenging fiscal year, reporting a net loss of HK$207.08 million for 2024, contrasting with the previous year's profit of HK$1.22 billion. The downturn is attributed to reduced revenue from property sales and lower recognition due to fewer project handovers amid a sluggish Mainland property market. Despite these challenges, the company maintains strong asset coverage with short-term assets exceeding liabilities and more cash than total debt. Its seasoned management and board provide stability as they navigate current market conditions, while recent dividend adjustments reflect ongoing financial recalibrations.
- Click to explore a detailed breakdown of our findings in Tian An China Investments' financial health report.
- Explore historical data to track Tian An China Investments' performance over time in our past results report.
Frencken Group (SGX:E28)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Frencken Group Limited is an investment holding company that offers original design, original equipment, and diversified integrated manufacturing solutions globally, with a market cap of SGD478.34 million.
Operations: The company's revenue is primarily generated from its Mechatronics segment, which accounts for SGD706.09 million, followed by the Integrated Manufacturing Services (IMS) segment at SGD85.68 million, and Investment Holding & Management Services contributing SGD11.53 million.
Market Cap: SGD478.34M
Frencken Group Limited's financial health is characterized by solid asset coverage, with short-term assets of SGD539.8 million surpassing both short- and long-term liabilities. The company has demonstrated stable earnings growth, reporting a net income increase to SGD37.12 million for 2024 from the previous year, alongside a dividend declaration of SGD0.0261 per share payable in May 2025. Despite its low Return on Equity at 8.4%, Frencken's interest payments are well-covered by EBIT, and its debt levels are manageable with more cash than total debt, reflecting prudent financial management amidst modest profit margin improvements and stable weekly volatility.
- Unlock comprehensive insights into our analysis of Frencken Group stock in this financial health report.
- Explore Frencken Group's analyst forecasts in our growth report.
Taking Advantage
- Access the full spectrum of 1,174 Asian Penny Stocks by clicking on this link.
- Interested In Other Possibilities? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Viva Biotech Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com